Literature DB >> 8258198

A limited sampling model for the pharmacokinetics of etoposide given orally.

D Gentili1, M Zucchetti, V Torri, C Sessa, J de Jong, F Cavalli, M D'Incalci.   

Abstract

A limited sampling model of etoposide after oral administration to estimate the area under the plasma concentration-time curve from 0 to 24 h (AUC) by determination of the drug plasma levels at only two time points was developed by a multiple regression analysis on a training data set of 15 patients receiving oral doses ranging from 54 to 90 mg/m2. The equation describing the model is AUC (micrograms ml-1 h) = 5.183 (micrograms ml-1 h) + 1.193 (h) x C1h (micrograms/ml) + 8.439 (h) x C4h (micrograms/ml) (R2 = 0.93, P = 0.0001), where C1h and C4h represent the plasma etoposide concentrations at 1 and 4 h, respectively. The model was validated prospectively on a test data set of 13 patients receiving oral doses ranging from 52 to 87 mg/m2 and, additionally, on a data set of 7 patients receiving oral doses ranging between 176 and 200 mg/m2, investigated in a previous study. Validation on both test data sets gave a relative mean predictive error of 0.1% and a relative root mean square error of 15.8% and 16.7%, respectively. The present study shows that it is possible to obtain a good estimate of the plasma AUC after oral administration of etoposide using a two-time-point sampling model. The model can be used to monitor the etoposide AUC in patients receiving chronic oral treatment.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8258198     DOI: 10.1007/bf00685894

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  14 in total

1.  Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial.

Authors:  D H Johnson; F A Greco; J Strupp; K R Hande; J D Hainsworth
Journal:  J Clin Oncol       Date:  1990-10       Impact factor: 44.544

2.  Limited sampling model for vinblastine pharmacokinetics.

Authors:  M J Ratain; N J Vogelzang
Journal:  Cancer Treat Rep       Date:  1987-10

3.  VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules.

Authors:  F Cavalli; R W Sonntag; F Jungi; H J Senn; K W Brunner
Journal:  Cancer Treat Rep       Date:  1978-03

4.  NL-FIT: a microcomputer program for non-linear fitting.

Authors:  G S Landriani; V Guardabasso; M Rocchetti
Journal:  Comput Programs Biomed       Date:  1983 Feb-Apr

5.  Variable bioavailability following repeated oral doses of etoposide.

Authors:  V J Harvey; M L Slevin; S P Joel; M M Smythe; A Johnston; P F Wrigley
Journal:  Eur J Cancer Clin Oncol       Date:  1985-11

6.  Etoposide: a pharmacokinetic profile including an assessment of bioavailability.

Authors:  D Cunningham; L McTaggart; M Soukop; J Cummings; G J Forrest; J F Stuart
Journal:  Med Oncol Tumor Pharmacother       Date:  1986

7.  A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer.

Authors:  M L Slevin; P I Clark; S P Joel; S Malik; R J Osborne; W M Gregory; D G Lowe; R H Reznek; P F Wrigley
Journal:  J Clin Oncol       Date:  1989-09       Impact factor: 44.544

8.  Pharmacokinetics of Teniposide (VM26) and etoposide (VP16-213) in children with cancer.

Authors:  W E Evans; J A Sinkule; W R Crom; L Dow; A T Look; G Rivera
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

9.  The effect of dose on the bioavailability of oral etoposide: confirmation of a clinically relevant observation.

Authors:  M L Slevin; S P Joel; R Whomsley; K Devenport; V J Harvey; R J Osborne; P F Wrigley
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

10.  Limited sampling models for amonafide (NSC 308847) pharmacokinetics.

Authors:  M J Ratain; A E Staubus; R L Schilsky; L Malspeis
Journal:  Cancer Res       Date:  1988-07-15       Impact factor: 12.701

View more
  8 in total

1.  Population pharmacokinetics and pharmacodynamics of oral etoposide.

Authors:  G Toffoli; G Corona; R Sorio; I Robieux; B Basso; A M Colussi; M Boiocchi
Journal:  Br J Clin Pharmacol       Date:  2001-11       Impact factor: 4.335

2.  A limited sampling method for the estimation of AUC and Cmax of carbamazepine and carbamazepine epoxide following a single and multiple dose of a sustained-release product.

Authors:  I Mahmood; N Chamberlin
Journal:  Br J Clin Pharmacol       Date:  1998-03       Impact factor: 4.335

Review 3.  Pharmacokinetic optimisation of treatment with oral etoposide.

Authors:  Giuseppe Toffoli; Giuseppe Corona; Barbara Basso; Mauro Boiocchi
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

4.  Limited and optimal sampling strategies for etoposide and etoposide catechol in children with leukemia.

Authors:  John Carl Panetta; Mark Wilkinson; Ching-Hon Pui; Mary V Relling
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-04       Impact factor: 2.745

5.  Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer.

Authors:  M J Millward; D R Newell; K Yuen; J P Matthews; K Balmanno; C J Charlton; L Gumbrell; M J Lind; F Chapman; M Proctor
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

6.  Oral treatment with etoposide in small cell lung cancer - dilemmas and solutions.

Authors:  Renata Rezonja; Lea Knez; Tanja Cufer; Ales Mrhar
Journal:  Radiol Oncol       Date:  2013-02-01       Impact factor: 2.991

7.  A study of the feasibility and accuracy of pharmacokinetically guided etoposide dosing in children.

Authors:  S P Lowis; L Price; A D Pearson; D R Newell; M Cole
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

8.  A limited sampling model for estimating pharmacokinetics of CPT-11 and its metabolite SN-38.

Authors:  Y Sasaki; S Mizuno; H Fujii; T Ohtsu; H Wakita; T Igarashi; K Itoh; I Sekine; Y Miyata; N Saijo
Journal:  Jpn J Cancer Res       Date:  1995-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.